ArticleThe oncologist2025
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.British journal of haematology · 2026Trial
- Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China.Frontiers in oncology · 2026Article
- Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundChronic lymphocytic leukemia (CLL) is considerably more common in Americans compared with Asians. The basis for these differences and implications for therapy outcomes are controversial and mostly unknown.
methodsWe compared baseline co-variates, therapies, and outcomes from 2 databases, Flatiron Health database in the United States (N = 15 786) and Tianjin CAMS database from China (N = 2996).
resultsChinese subjects had younger age at diagnosis, more advanced Rai stage and an increased prevalence of lymphadenoma, thrombocytopenia, and increased β2-microglobulin. Americans had higher rates of unmutated IGHV, TP53 deletion, and cytogenetic abnormalities. These differences persisted after adjusting for age, Rai stage, and IGHV mutation state. There were also substantial differences in therapy patterns between the cohorts. Median survival in Chinese was 9.7 vs 7.5 years in Americans (P < .001). In sub-group analyses, Chinese CLL had better 5-year survivals with chemotherapy (69% [95% CI, 66, 72%] vs 49% [47, 52%]; P < .001), immune therapies (67% [63, 72%] vs 65% [64, 66%]; P = .041), and targeted therapies (85% [81, 88%] vs 65% [64, 67%]; P < .001). These advantages were pronounced among older patients and those with early-stage, mutated IGHV and without TP53 deletion.
conclusionThis cross-sectional study identifies significant clinical and treatment outcome disparities in CLL between Eastern and Western populations, attributed to distinct genetic and molecular profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.